Outcomes of Treatment of Choroidal Neovascularization Associated With Central Serous Chorioretinopathy With Intravitreal Antiangiogenic Agents

Abstract

Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.

Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy

“…On average, only 4.4 anti-VEGF injections were required over a period of 1.5 years to secondary CNV, 42 in contrast to approximately 13 injections required over a 2 year period for treatment of neovascular age-related macular degeneration. 43 …”

Statement of the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration

“…Here again, good efficacy that appears similar to that of ranibizumab was generally seen, e. g., in angioid streaks [8], CSC-related CNV [40,41], inflammatory CNV [19], and idiopathic CNV [40,42]. With regard to aflibercept, there are at present primarily isolated case reports that similarly point to good efficacy [41,43,44]. An open-label phase I/II study has also been published on the treatment of CNV secondary to POHS, demonstrating the efficacy of aflibercept treatment in POHSrelated CNV with two different treatment strategies [45].…”

“…There are numerous case series, some of which are prospective but most of which are retrospective, on bevacizumab for other indications. Here again, good efficacy that appears similar to that of ranibizumab was generally seen, e. g., in angioid streaks [8], CSC-related CNV [40,41], inflammatory CNV [19], and idiopathic CNV [40,42]. With regard to aflibercept, there are at present primarily isolated case reports that similarly point to good efficacy [41,43,44].…”

Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Therapie choroidaler Neovaskularisationen bei anderen Erkrankungen als der neovaskulären altersabhängigen Makuladegeneration

“…Generell zeigte sich auch hier eine gute Wirksamkeit, die ähnlich derjenigen von Ranibizumab zu sein scheint, so z. B. bei angioiden Streifen [8], CCS-assoziierter CNV [40,41], inflammatorischer CNV [19] oder idiopathischer CNV [40,42]. Im Hinblick auf Aflibercept existieren derzeit vorwiegend einzelne Fallberichte, die jedoch ebenfalls auf eine gute Wirksamkeit hindeuten [41,43,44].…”

“…B. bei angioiden Streifen [8], CCS-assoziierter CNV [40,41], inflammatorischer CNV [19] oder idiopathischer CNV [40,42]. Im Hinblick auf Aflibercept existieren derzeit vorwiegend einzelne Fallberichte, die jedoch ebenfalls auf eine gute Wirksamkeit hindeuten [41,43,44]. Zur Behandlung der CNV bei POHS ist weiterhin eine Open-Label-Phase-I/II-Studie publiziert worden, welche die Wirksamkeit einer Aflibercepttherapie bei POHS-assoziierter CNV mit 2 unterschiedlichen Behandlungsstrategien nachweisen konnte [45].…”